Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

A lack or decrease of clotting factor IX (FIX) causes hemophilia B, also called Christmas disease. Hemophilia B is four times less common than hemophilia A, according to the National Hemophilia ...

The approval keeps uniQure in pole position over its closest rival in the haemophilia B gene therapy race, Pfizer/Roche, whose fidanacogene elaparvovec candidate is in the BENEGENE-2 trial, due to ...

Hemophilia B treatment typically involves regular factor IX infusions. The latest research includes two gene therapy drugs that may reduce the need for these infusions. Though research is still ...

more than 38,000 people worldwide were living with haemophilia B in 2021. Pfizer's BENEGENE-2 study met its primary endpoint of non-inferiority and superiority in the annualised bleeding rate (ABR ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

New treatments have changed the face of managing hemophilia with an inhibitor, columnist Cazandra Campos-MacDonald writes.

Columnist Alliah Czarielle urges those with hemophilia to remember the power of movement, even if they sense that activity invites trouble.